ST Wanbang's wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., recently received the Drug Registration Certificate for Sulpiride Tablets issued by the National Medical Products Administration. The specification is 0.1 grams, and the registration classification is chemical drug category 3, which is deemed to have passed the generic drug quality and efficacy consistency evaluation. Sulpiride Tablets are included in the 2025 National Medical Insurance Drug List and the 2026 National Essential Drug List. As a benzamide antipsychotic, it is used to treat schizophrenia, has some efficacy for depressive symptoms, and also has antiemetic and gastric secretion inhibitory effects. The company stated that this approval enriches its product line for antipsychotic medications and strengthens the advantage of its integrated model of active pharmaceutical ingredients and finished drugs. At the same time, it cautioned that drug production and sales are affected by factors such as national policies and market conditions, and there is considerable uncertainty.
Wanbangde Pharmaceutical Holding Group Co LtdSubsidiary obtained drug registration certificate for Sulpiride Tablets, deemed to pass consistency evaluation, enriching product line.